All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration

被引:213
作者
Lewden, Charlotte [1 ]
Bouteloup, Vincent [1 ]
De Wit, Stephane [2 ]
Sabin, Caroline [3 ]
Mocroft, Amanda [3 ]
Wasmuth, Jan Christian [4 ]
van Sighem, Ard [5 ]
Kirk, Ole [6 ,7 ]
Obel, Niels [7 ]
Panos, George [8 ,9 ]
Ghosn, Jade [10 ]
Dabis, Francois [1 ]
Mary-Krause, Murielle [11 ,12 ]
Leport, Catherine [13 ]
Perez-Hoyos, Santiago [14 ]
Sobrino-Vegas, Paz [15 ]
Stephan, Christoph [16 ]
Castagna, Antonella [17 ]
Antinori, Andrea [18 ]
Monforte, Antonella d'Arminio [19 ]
Torti, Carlo [20 ,21 ]
Mussini, Cristina [22 ]
Isern, Virginia [23 ]
Calmy, Alexandra [24 ]
Teira, Ramon [25 ]
Egger, Matthias [26 ]
Grarup, Jesper [27 ]
Chene, Genevieve [1 ]
机构
[1] Univ Bordeaux Segalen, ISPED, INSERM, U897, F-33076 Bordeaux, France
[2] St Pierre Univ Hosp, Dept Infect Dis, Brussels, Belgium
[3] UCL Med Sch, Res Dept Infect & Populat Hlth, London, England
[4] Univ Bonn, Dept Internal Med 1, Bonn, Germany
[5] Stichting HIV Monitoring, Amsterdam, Netherlands
[6] Univ Copenhagen, Fac Hlth Sci, Copenhagen HIV Programme, Copenhagen, Denmark
[7] Univ Copenhagen, Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark
[8] Univ Patras, Gen Hosp, Dept Internal Med & Infect Dis, Patras, Achaia, Greece
[9] 1st IKA Gen Hosp, Patras, Achaia, Greece
[10] Bicetre Univ Hosp, APHP, Dept Internal Med & Infect Dis, Le Kremlin Bicetre, France
[11] INSERM, U943, Paris, France
[12] Univ Paris 06, UPMC, UMR S943, Paris, France
[13] Univ Paris 07, INSERM, Unite Coordinat Risque Epidem & Biol, UFR Med,UMR S 738,APHP, Paris, France
[14] Vall Hebron Hosp Res Inst VHIR, Methodol Support Unit Biomed Res USMIB, Barcelona, Spain
[15] Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid, Spain
[16] Hosp Johann Wolfgang Goethe Univ Med Ctr, HIVCTR, Frankfurt, Germany
[17] Ist Sci San Raffaele, Dept Infect & Trop Dis, I-20132 Milan, Italy
[18] IRCCS, Natl Inst Infect Dis Lazzaro Spallanzani, Clin Dept, Rome, Italy
[19] Polo Univ Azienda Osped San Paolo, Dipartimento Med, Clin Malattie Infett & Tropicali Chirurg & Odonto, Milan, Italy
[20] Spedali Civil Brescia, HIV AIDS Unit, Dept Infect Dis, I-25125 Brescia, Italy
[21] Univ Brescia, Brescia, Italy
[22] Policlin Modena, Clin Infect Dis, Modena, Italy
[23] Ctr Epidemiol Studies HIV AIDS Catalonia CEEISCAT, Barcelona, Spain
[24] Univ Hosp Geneva, Dept Infect Dis, Geneva, Switzerland
[25] Hosp Sierrallana Torrelavega, Serv Med Interna, Cantabria, Spain
[26] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland
[27] Univ Copenhagen, Fac Hlth Sci, CHIP, Dept Int Hlth Immunol & Microbiol, Copenhagen, Denmark
关键词
HIV infection; CD4 lymphocyte count; mortality; anti-retroviral therapy; highly active; COMBINATION ANTIRETROVIRAL THERAPY; INHIBITOR-CONTAINING THERAPY; DEFINING MALIGNANCIES; DEATH RATES; CELL COUNT; IMMUNODEFICIENCY; AIDS; INDIVIDUALS; INITIATION; LEVEL;
D O I
10.1093/ije/dyr164
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Using data from a large European collaborative study, we aimed to identify the circumstances in which treated HIV-infected individuals will experience similar mortality rates to those of the general population. Methods Adults were eligible if they initiated combination anti-retroviral treatment (cART) between 1998 and 2008 and had one prior CD4 measurement within 6 months. Standardized mortality ratios (SMRs) and excess mortality rates compared with the general population were estimated using Poisson regression. Periods of follow-up were classified according to the current CD4 count. Results Of the 80 642 individuals, 70% were men, 16% were injecting drug users (IDUs), the median age was 37 years, median CD4 count 225/mm(3) at cART initiation and median follow-up was 3.5 years. The overall mortality rate was 1.2/100 person-years (PY) (men: 1.3, women: 0.9), 4.2 times as high as that in the general population (SMR for men: 3.8, for women: 7.4). Among 35 316 individuals with a CD4 count epsilon 500/mm(3), the mortality rate was 0.37/100 PY (SMR 1.5); mortality rates were similar to those of the general population in non-IDU men [SMR 0.9, 95% confidence interval (95% CI) 0.7-1.3] and, after 3 years, in women (SMR 1.1, 95% CI 0.7-1.7). Mortality rates in IDUs remained elevated, though a trend to decrease with longer durations with high CD4 count was seen. A prior AIDS diagnosis was associated with higher mortality. Conclusions Mortality patterns in most non-IDU HIV-infected individuals with high CD4 counts on cART are similar to those in the general population. The persistent role of a prior AIDS diagnosis underlines the importance of early diagnosis of HIV infection.
引用
收藏
页码:433 / 445
页数:13
相关论文
共 8 条
  • [1] HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population
    Lewden, Charlotte
    Chene, Genevieve
    Morlat, Philippe
    Raffi, Francois
    Dupon, Michel
    Dellamonica, Pierre
    Pellegrin, Jean-Luc
    Katlama, Christine
    Dabis, Francois
    Leport, Catherine
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (01) : 72 - 77
  • [2] Mortality and its predictors among antiretroviral therapy naive HIV-infected individuals with CD4 cell count ≥350 cells/mm3 compared to the general population: data from a population-based prospective HIV cohort in Uganda
    Masiira, Ben
    Baisley, Kathy
    Mayanja, Billy N.
    Kazooba, Patrick
    Maher, Dermot
    Kaleebu, Pontiano
    GLOBAL HEALTH ACTION, 2014, 7 : 1 - 11
  • [3] Rate and Predictors of Non-AIDS Events in a Cohort of HIV-Infected Patients with a CD4 T Cell Count Above 500 Cells/mm3
    Lucero, Constanza
    Torres, Berta
    Leon, Agathe
    Calvo, Marta
    Leal, Lorna
    Perez, Inaki
    Plana, Montserrat
    Arnedo, Mireia
    Mallolas, Josep
    Gatell, Josep M.
    Garcia, Felipe
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (08) : 1161 - 1167
  • [4] One year survival of HIV-infected veterans with CD4 100 cells/mm3: data from a veteran cohort
    Breaux, Katharine
    Gadde, Susmitha
    Graviss, Edward A.
    Rodriguez-Barradas, Maria C.
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2010, 22 (07): : 886 - 894
  • [5] Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3
    Pollard, RB
    Peterson, D
    Hardy, D
    Pottage, J
    Murphy, RL
    Gathe, J
    Beall, G
    Rutkievicz, V
    Reynolds, L
    Cross, AP
    Dunkle, LM
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 22 (01) : 39 - 48
  • [6] Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria
    Gilks, Charles F.
    Walker, A. Sarah
    Munderi, Paula
    Kityo, Cissy
    Reid, Andrew
    Katabira, Elly
    Goodall, Ruth L.
    Grosskurth, Heiner
    Mugyenyi, Peter
    Hakim, James
    Gibb, Diana M.
    PLOS ONE, 2013, 8 (02):
  • [7] Incidence of Malignancies in HIV-Infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort Study
    Prosperi, M. C. F.
    Cozzi-Lepri, A.
    Castagna, A.
    Mussini, C.
    Murri, R.
    Giacometti, A.
    Torti, C.
    Costantini, A.
    Narciso, P.
    Ghinelli, F.
    Antinori, A.
    Monforte, A. d'Arminio
    CLINICAL INFECTIOUS DISEASES, 2010, 50 (09) : 1316 - 1321
  • [8] Association of CD4 T cell count and optimal timing of antiretroviral therapy initiation with immune reconstitution inflammatory syndrome and all-cause mortality for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis
    Li, Lifang
    Li, Jianqiang
    Chai, Chunwei
    Liu, Tanzhen
    Li, Pingping
    Qu, Mengrui
    Zhao, Hui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2021, 14 (06): : 670 - 679